Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. Finally, Crossmark Global Holdings Inc. raised its stake in shares of Nektar Therapeutics by 2.8% in the 4th quarter. Artal Group Sa who had been investing in Nektar Therapeutics (Call) for a number of months, seems to be less bullish one the $11.91B market cap company. Swiss National Bank raised its stake in shares of Nektar Therapeutics by 2.6% in the 4th quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company's stock worth $79,903,000 after acquiring an additional 1,556,352 shares during the last quarter. Amalgamated Bank now owns 21,775 shares of the biopharmaceutical company's stock worth $1,300,000 after buying an additional 1,298 shares in the last quarter. The institutional investor held 563,557 shares of the energy company at the end of 2017Q3, valued at $20.14M, up from 546,234 at the end of the previous reported quarter. Currently Nektar Therapeutics (NKTR) stock is moving with Upswing trend. Alps Advsrs holds 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 153,958 shares. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher A. Kuebler sold 30,000 shares of the firm's stock in a transaction dated Tuesday, January 2nd. Earlier this month, John Nicholson, the SVP & Chief Operating Officer of NKTR bought 120,000 shares for a total of $1,360,800. Following the completion of the sale, the director now directly owns 70,500 shares in the company, valued at $4,135,530. The disclosure for this purchase can be found here. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company's stock valued at $254,000 after purchasing an additional 929 shares during the last quarter. Fairfield Bush & owns 12,000 shares or 0.09% of their U.S. portfolio.
"We expect both Nektar and BMY to jointly report clinical data going forward.", the firm's analyst commented.
Currently, the analyst consensus on Nektar Therapeutics is Strong Buy and the average price target is $85.67, representing a 13.2% upside.
Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter's lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact. Mizuho reissued a "buy" rating and set a $89.00 price objective on shares of Nektar Therapeutics in a report on Wednesday. Canaccord Genuity restated a "buy" rating and set a $80.00 price target (up previously from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Jefferies maintained it with "Buy" rating and $23.0 target in Wednesday, October 18 report. Roth Capital maintained the stock with "Buy" rating in Thursday, July 20 report. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock.
Stocks Raising Investors Eye Brows: Lam Research Corporation (NASDAQ:LRCX)
Cowen & Co maintained Lam Research Corporation (NASDAQ:LRCX) on Thursday, December 10 with "Outperform" rating. (NASDAQ:FB). Lam Research Corporation (NASDAQ:LRCX) closed down -0.39 points or -0.23% at $172.56 with 2.83 mln shares exchanging hands.
Based on a recent bid, this stock (NKTR) was trading at a distance of 1.28% from 20 days simple moving average, and its distance from 50 days simple moving average is 20.05% while it has a distance of 133.88% from the 200 days simple moving average. Nektar Therapeutics has a 1-year low of $12.50 and a 1-year high of $99.02.
Rothschild Ptnrs Limited Liability Corp reported 0.63% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Geode Mgmt Ltd Company reported 1.43 million shares or 0.01% of all its holdings. The firm had revenue of $1.55 million during the quarter, compared to analysts' expectations of $1.38 million. The return on assets stands at -19.5%, Return on Equity now is -190.7% and the Return on Investment value is -33.8%. Qs Ltd Limited Liability Company holds 0% or 3,600 shares.
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are created to meet unmet medical needs and improve the benefits of drugs for patients. The Company's product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.